Drug Trial Radar · NCT06800404
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Actual
Start
May 2, 2025
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Hope Biosciences Research FoundationIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Multiple Sclerosis
Interventions
Autologous HB-adMSCsDrug
Autologous HB-adMSCs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument scoresTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hope Biosciences Research Foundation
Sugar Land, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.